Cadrenal Therapeutics Inc CVKD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
-
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
-
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
-
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
-
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
-
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
Trading Information
- Previous Close Price
- $1.02
- Day Range
- $0.96–1.07
- 52-Week Range
- $0.82–14.21
- Bid/Ask
- $0.97 / $1.07
- Shares Outstanding
- 3.57M
- Market Cap
- $3.46M
- Volume/Avg
- 19,769 / 458,189
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.cadrenal.com
Valuation
|
Metric
|
CVKD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CVKD
|
|---|---|
Quick Ratio | 3.39 |
Current Ratio | 3.73 |
Interest Coverage | — |
Quick Ratio
CVKD
Profitability
|
Metric
|
CVKD
|
|---|---|
Return on Assets (Normalized) | −214.96% |
Return on Equity (Normalized) | −313.54% |
Return on Invested Capital (Normalized) | −317.04% |
Return on Assets
CVKD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|qKBycgX | LOCK|@Ph$P | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?qf!><! | LOCK|?^&bW | $84B | |||
| Moderna Inc
MRNA
| LOCK|@t%$S$G | LOCK|&b | $81B | |||
| argenx SE ADR
ARGX
| LOCK|XmzsYW | LOCK|>t | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Fbc>C$g | LOCK|<$ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cpPz<dK | LOCK|>^!M> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%&#<P&r | LOCK|#<YNb | $28B | |||
| Incyte Corp
INCY
| LOCK|>CKW@tN | LOCK|gj< | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Zs^l^ZV | LOCK|Z?% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|knpvx^D | LOCK|&n% | $14B |
United States